Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

Intangible Assets

9 Months Ended

Aug. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Note 4 – Intangible Assets

The Company incurs certain legal and related costs in connection with patent and trademark applications. If a future economic benefit is anticipated from the resulting patent or trademark or an alternate future use is available to the Company, such costs are capitalized and amortized over the expected life of the patent or trademark. The Company’s assessment of future economic benefit involves considerable management judgment. A different conclusion could result in the reduction of the carrying value of these assets.

Intangible assets were as follows as of August 31, 2024 and November 30, 2023:


	Useful lives	August 31, 2024			November 30, 2023
Patents	10-20 years	$	697,744		$	697,744
Less: Intangible asset impairment			(377,810	)		(377,810	)
Less: Accumulated amortization			(169,152	)		(160,434	)
License agreement	10 years		474,000			474,000
Less: Intangible asset impairment			(185,000	)		(185,000	)
Less: Accumulated amortization			(266,193	)		(248,607	)
Customer relationships – PrepaCyte®CB	15 years		41,000			41,000
Less: Intangible asset impairment			(26,267	)		(26,267	)
Less: Accumulated amortization			(10,101	)		(9,505	)
Brand	1 year		31,000			31,000
Less: Accumulated amortization			(31,000	)		(31,000	)
Customer relationships – Cord:Use	30 years		960,000			960,000
Less: Accumulated amortization			(200,000	)		(176,000	)
Net Intangible Assets		$	938,221		$	989,121

Amortization expense of intangibles was approximately $17,000 and $24,000 for the three months ended August 31, 2024 and August 31, 2023, respectively. Amortization expense of intangibles was approximately $51,000 and $72,000 for the nine months ended August 31, 2024 and August 31, 2023.